An interventional study of Ketamine and Etomidate in Hemodynamically Unstable Patients, Emergency Surgery and Ketamine, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This work aimed to assess the hemodynamic effects of ketamine versus etomidate with or without midazolam as induction agents in patients undergoing emergency surgery.
Hemodynamic instability is a frequent and critical challenge in individuals undergoing emergency surgery. The induction of general anesthesia in such patients carries a significant risk of cardiovascular compromise, including hypotension, reduced cardiac output, and peri-induction circulatory collapse.
Etomidate has long been preferred for unstable patients because it produces minimal myocardial depression and preserves sympathetic tone, resulting in comparatively stable blood pressure (BP) and heart rate (HR).
Ketamine, a dissociative anesthetic and NMDA receptor antagonist, has a distinctive hemodynamic profile characterized by indirect sympathomimetic stimulation, leading to increased HR, BP, and cardiac output through enhanced catecholamine activity.
Midazolam, a short-acting benzodiazepine, is frequently co-administered with induction agents to enhance sedation and provide amnesia.
Al-Azhar University is the lead sponsor of 535 studies on the registry; 173 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received intravenous ketamine 2 mg/kg.
Drug: Ketamine
Patients received etomidate 0.3 mg/kg.
Drug: Etomidate
Patients received ketamine 1.5 mg/kg and midazolam 2 mg.
Drug: Ketamine + Midazolam
Patients received etomidate 0.2 mg/kg and midazolam 2 mg.
Drug: Etomidate + Midazolam
Patients received intravenous ketamine 2 mg/kg.
Patients received etomidate 0.3 mg/kg.
Drug pages: Ketamine · Midazolam
Patients received ketamine 1.5 mg/kg and midazolam 2 mg.
Patients received etomidate 0.2 mg/kg and midazolam 2 mg.
Mean arterial pressure at 10 minutes
Mean arterial pressure was noted before induction and at 1, 3, 5, and 10 minutes following induction.
Time frame: 10 minutes following induction.
Mean arterial pressure at 15 minutes
Mean arterial pressure was noted before induction and at 1, 3, 5, 10 and 15 minutes following induction.
Time frame: 15 minutes following induction.
Mean arterial pressure at 5 minutes
Mean arterial pressure was noted before induction and at 1, 3, 5, 10 and 15 minutes following induction.
Time frame: 5 minutes following induction.
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Ran from Jul 2024 to primary completion in Feb 2025, 7 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketamine · Etomidate · Midazolam